Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT01572909

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Stealth BioTherapeutics Inc. (from the registry)
Registry
  • NCT NCT01572909
Other papers using this trial's data
  • Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial) The American journal of cardiology, 2016-09-01 DOI, PubMed 27392509

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Hungary, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01572909. Randomized; triple masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2020-06-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
Acronym
EMBRACE
Condition
Reperfusion Injury
Condition
STEMI
Intervention (Drug)
Bendavia (MTP-131)
Intervention (Drug)
Placebo
Lead sponsor
Stealth BioTherapeutics Inc. (class: industry)
Collaborator
ICON Clinical Research (class: industry)

Record details

Record id
cardio:ct-nct01572909
Content hash
ac1c7ffcd6a62b614ccd161e45f3b5b6119661812ca1769a2d68414f19aa0d0a